Brian Lestini

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Dermatology, Oncology +13

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready, Matthew D. Hellmann, Mark M. Awad et al. · Journal of Clinical Oncology · 2019 · 596 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky et al. · Cancer Research · 2011 · 217 citations · Full text

Medicine, Oncology, Pharmacology +15